OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, courtesy of its potential in RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE’s performance and strategic ...
OPKO Health is refocusing on drug development, selling BioReference Lab assets to strengthen its balance sheet and fund its pipeline. OPK's shift to a co-development and royalty model aims to reduce ...
OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) CEO Phillip Md Et Al Frost acquired 150,000 shares of the firm’s stock in a transaction dated Friday, March 28th. The shares were acquired at an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback